glp-1 analog drugs analogs, new trend in obesity treatment, become even more effective < Pharma < Article GLP1 Receptor Agonists—Effects beyond Obesity

Physical activity/exercise and diabetes: A position statement of the american diabetes association

This might trigger the body to release GLP-1, aiding in appetite regulation and potentially supporting weight loss efforts

The trials included individuals with obesity or overweight conditions, with or without Type 2 diabetes

GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management

For other medicines like semaglutide, exenatide, liraglutide, dulaglutide, or lixisenatide, there is no proof that they make the pill less effective

doi: 10.1172/jci.insight.153732 [DOI] [PMC free article] [PubMed] [Google Scholar] 270